AVROBIO reports Q2 2022 net loss of $28.1M, cash runway into Q1 2024

Tectonic Therapeutic, Inc.

2022-Q2 EPS reported -$1.32

Net loss of $28.1M in Q2 2022 vs $31.4M in Q2 2021; R&D expenses $18.9M, down from $22.5M.
Cash and equivalents $132.4M as of June 30, 2022, down from $189.6M at Dec 31, 2021; runway into Q1 2024.
All five patients in Phase 1/2 cystinosis trial remain off oral cysteamine post gene therapy.
FDA Orphan Drug Designation granted for AVR-RD-05 in Hunter syndrome; CTA authorization expected 2H 2022.
Plan to engage with regulators on cystinosis and Gaucher type 3 clinical strategies in 2H 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.